Regeneron Wades Deeper Into Oncology With Ambitions To Be A Force In The Space

 
• By Jessica Merrill

Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.

David Weinreich
Regeneron's David Weinreich • Source: Regeneron

More from Anticancer

More from Therapy Areas